Kevin Lee Sells 5,905 Shares of Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,905 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer directly owned 605,408 shares in the company, valued at approximately $2,585,092.16. The trade was a 0.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, July 6th, Kevin Lee sold 1,737 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $4.31, for a total value of $7,486.47.

Bicycle Therapeutics Trading Down 2.3%

NASDAQ BCYC opened at $4.28 on Thursday. The business has a fifty day simple moving average of $4.38 and a 200 day simple moving average of $5.24. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $3.92 and a 12 month high of $9.18. The firm has a market capitalization of $298.79 million, a P/E ratio of -1.36 and a beta of 1.55.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $7.50 million. As a group, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Man Group plc increased its position in Bicycle Therapeutics by 4.8% in the fourth quarter. Man Group plc now owns 42,860 shares of the company’s stock worth $303,000 after buying an additional 1,969 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after buying an additional 2,243 shares during the last quarter. Flax Pond Capital LLC grew its stake in shares of Bicycle Therapeutics by 1.4% during the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock worth $817,000 after acquiring an additional 2,503 shares during the period. Ameriprise Financial Inc. increased its holdings in Bicycle Therapeutics by 21.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after acquiring an additional 2,668 shares during the last quarter. Finally, Clearstead Advisors LLC raised its stake in Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares during the period. Institutional investors own 86.15% of the company’s stock.

Wall Street Analyst Weigh In

BCYC has been the subject of several analyst reports. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Jefferies Financial Group reiterated a “buy” rating and set a $12.00 price target on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Needham & Company LLC cut their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Morgan Stanley reduced their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 8th. Finally, Citizens Jmp lowered their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 18th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.00.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.